Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19173048 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL29125008 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2744005 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL30954764 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL203262 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL19172281 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL23015072 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1069647 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2786532 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1009635 | 1.00 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12397058-B2 | Metabolically stable prodrugs | TSRL, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| WO-2025122011-A9 | TRIGLYCERIDE ANALOGS | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025122011-A1 | TRIGLYCERIDE ANALOGS | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2025-06-12 | — | — | WO | disclosed |
| EP-4561585-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | Sanifit Therapeutics S.A. (ES) | 2025-06-04 | — | — | EP | disclosed |
| CN-119855595-A | IP4-4,6 substituted derivative compounds for treating ectopic calcification, inhibiting progression and preventing ectopic calcification | 萨尼菲特治疗有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20250011287-A1 | FLUORINE-CONTAINING COMPOUND AND CONTRAST AGENT | TDK CORPORATION (JP) | 2025-01-09 | — | — | US | disclosed |
| CN-118613471-A | Fluorochemical and contrast agent | TDK株式会社 | 2024-09-06 | — | — | CN | disclosed |
| US-12060323-B2 | 6-hydroxy-3-hexenyl alkoxymethyl ether compound and a process for preparing a 3,13-octadecadien-1-ol compound from the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-08-13 | — | — | US | disclosed |
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | VIFOR (INTERNATIONAL) LTD. (CH) | 2024-04-04 | — | — | US | disclosed |
| WO-2024023359-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | SANIFIT THERAPEUTICS, S.A. (ES) | 2024-02-01 | — | — | WO | disclosed |
| EP-2268606-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009132978-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2008044033-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-04-17 | — | — | WO | disclosed |
| EP-1803150-A1 | COMPOUNDS FOR MYOCARDIAL PERFUSION IMAGING | Bristol-Myers Squibb Pharma Company (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044280-A1 | COMPOUNDS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060083681-A1 | Compounds for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. | 2006-04-20 | — | — | US | disclosed |
| US-5801202-A | Amine derivatives for treatment of skin disorders | KAO COPRORATION (JP) | 1998-09-01 | — | — | US | disclosed |
| EP-0790977-A1 | AMINE DERIVATIVES FOR TREATMENT OF SKIN DISORDERS | Kao Corporation (JP) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015098-A1 | AMINE DERIVATIVES FOR TREATMENT OF SKIN DISORDERS | KAO CORPORATION (JP) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | MEN1 2587/4885KMT2A 731/4885KDM4C 1718/4885 |
| US-12060323-B2 | 6-hydroxy-3-hexenyl alkoxymethyl ether compound and a process for preparing a 3,13-octadecadien-1-ol compound from the same | CYP8B1, CYP2E1, OXER1 | MEN1 2297/4885KMT2A 960/4885KDM4C 356/4885 |
| US-20250011287-A1 | FLUORINE-CONTAINING COMPOUND AND CONTRAST AGENT | AFF1, AFF2, ZRANB2 | MEN1 117/4885KMT2A 1168/4885KDM4C 1000/4885 |
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | IPO4, TPX2, IPO9 | MEN1 2984/4885KMT2A 4555/4885KDM4C 1274/4885 |
| US-20060083681-A1 | Compounds for myocardial perfusion imaging | TNNI3, FABP3, TNNT2 | MEN1 1701/4885KMT2A 4785/4885KDM4C 4496/4885 |
| US-12397058-B2 | Metabolically stable prodrugs | CES1, CES2, CYP2S1 | MEN1 1968/4885KMT2A 3952/4885KDM4C 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.